Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 2, 2010, Pages 362-368

  Treeprasertsuk, Sombat ^a   Silachamroon, Udomsak ^b   Krudsood, Srivicha ^b   Huntrup, Arun ^b   Suwannakudt, Plengsakoon ^b   Vannaphan, Suparp ^b   Wilairatana, Polrat ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Artesunate; Falciparum malaria; Jaundice; Ursodeoxycholic acid

Indexed keywords

ARTESUNATE; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBINOPATHY; HUMAN; INTENSIVE CARE UNIT; JAUNDICE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PRIORITY JOURNAL; SEX RATIO; TREATMENT RESPONSE;

EID: 76149085827     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06007.x     Document Type: Article

References (49)

1. World Health Organization. Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg. 1990 84 (Suppl. 2 1 65.
2. Wilairatana P, Looareesuwan S. Guideline in management of severe malaria. J. Indian Med. Assoc. 2000 98 : 628 631.
3. Looareesuwan S, Olliaro P, White NJ et al. Consensus recommendation on the treatment of malaria in Southeast Asia. Southeast Asian J. Trop. Med. Public Health 1998 29 : 355 360.
4. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005 366 : 717 725.
5. Newton PN, Angus BJ, Chierakul W et al. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin. Infect. Dis. 2003 37 : 7 16.
6. Mishra SK, Mohanty S, Das BS et al. Hepatic changes in P. falciparum malaria. Indian J. Malariol. 1992 29 : 167 171.
7. Wilairatana P, Looareesuwan S, Charoenlarp P. Liver profile changes and complications in jaundiced patients with falciparum malaria. Trop. Med. Parasitol. 1994 45 : 298 302.
8. Anand AC, Ramji C, Narula AS, Singh W. Malarial hepatitis: a heterogeneous syndrome? Natl. Med. J. India 1992 5 : 59 62.
9. Ramachandran S, Perera MV. Jaundice and hepatomegaly in primary malaria. J. Trop. Med. Hyg. 1976 79 : 207 210.
10. Kochar DK, Agarwal P, Kochar SK et al. Hepatocyte dysfunction and hepatic encephalopathy in Plasmodium falciparum malaria. QJM 2003 96 : 505 512.
11. Dash SC, Bhuyan UN, Gupta A, Sharma LC, Kumar A, Agarwal SK. Falciparum malaria complicating cholestatic jaundice and acute renal failure. J. Assoc. Physicians India 1994 42 : 101 102.
12. Nacher M, Treeprasertsuk S, Singhasivanon P et al. Association of hepatomegaly and jaundice with acute renal failure but not with cerebral malaria in severe falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 2001 65 : 828 833.
13. Blumberg L, Lee RP, Lipman J, Beards S. Predictors of mortality in severe malaria: a two year experience in a non-endemic area. Anaesth. Intensive Care 1996 24 : 217 223.
14. Srivastava A, Khanduri A, Lakhtakia S, Pandey R, Choudhuri G. Falciparum malaria with acute liver failure. Trop. Gastroenterol. 1996 17 : 172 174.
15. Palmer RH. Bile acids, liver injury, and liver disease. Arch. Intern. Med. 1972 130 : 606 617.
16. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002 36 : 525 531.
17. Bacq Y, Sapey T, Brechot MC, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 1997 26 : 358 364.
18. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 113 : 884 890.
19. Katsinelos P, Vasiliadis T, Xiarchos P et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur. J. Gastroenterol. Hepatol. 2000 12 : 365 368.
20. Rachima CM, Cohen E, Garty M. Acute hepatitis A: combination of the relapsing and the cholestatic forms, two rare variants. Am. J. Med. Sci. 2000 319 : 417 419.
21. Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J. Hepatol. 2003 39 : 112 114.
22. Fabris P, Tositti G, Mazzella G et al. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment. Pharmacol. Ther. 1999 13 : 1187 1193.
23. World Health Organization CDC. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2000 94 (Suppl. 1 S1 S90.
24. Mishra SK, Pati SS, Satpathy SK, Mohanty S, Mohapatra DN. The influence of hyperbilirubinaemia on malaria-related mortality: an analysis of 1103 patients. Ann Trop. Med. Parasitol. 2004 98 : 555 558.
25. Looareesuwan S, Wilairatana P, Vannaphan S et al. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 1998 58 : 348 353. (Pubitemid 28160759)
26. Treeprasertsuk S, Krudsood S, Tosukhowong T et al. N-acetylcysteine in severe falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 2003 34 : 37 42.
27. Watt G, Jongsakul K, Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM 2002 95 : 285 290.
28. Ahsan T, Ali H, Bkaht SF et al. Jaundice in falciparum malaria; changing trends in clinical presentation - a need for awareness. J. Pak. Med. Assoc. 2008 58 : 616 621.
29. Das SN, Mohapatra B, Mohanty R, Dash PC, Kar K, Dash PK. Malarial hepatitis as a component of multiorgan failure - a bad prognostic sign. J. Indian Med. Assoc. 2007 105 : 247 250.
30. Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am. J. Trop. Med. Hyg. 2007 77 : 779 789.
31. Ghosh K, Ghosh K. Pathogenesis of anemia in malaria: a concise review. Parasitol. Res. 2007 101 : 1463 1469.
32. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 1997 336 : 691 695.
33. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J. Hepatol. 2008 48 : 792 800.
34. Visith S, Kearkiat P. Nephropathy in leptospirosis. J. Postgrad. Med. 2005 51 : 184 188.
35. Sitprija V. Renal dysfunction in leptospirosis: a view from the tropics. Nat. Clin. Pract. Nephrol. 2006 2 : 658 659.
36. Sitprija V. Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis. Nat. Clin. Pract. Nephrol. 2008 4 : 91 101.
37. Kucuk C, Sozuer E, Ikizceli I et al. Role of oxygen free radical scavengers in acute renal failure complicating obstructive jaundice. Eur. Surg. Res. 2003 35 : 143 147.
38. Sitprija V, Chusilp S. Renal failure and hyperbilirubinaemia in leptospirosis. Treatment with exchange transfusion. Med. J. Aust. 1973 1 : 171 173.
39. Sitprija V, Napathorn S, Laorpatanaskul S et al. Renal and systemic hemodynamics, in falciparum malaria. Am. J. Nephrol. 1996 16 : 513 519. (Pubitemid 26387937)
40. Tse KC, Yip PS, Hui KM et al. Potential benefit of plasma exchange in treatment of severe icteric leptospirosis complicated by acute renal failure. Clin. Diagn. Lab. Immunol. 2002 9 : 482 484.
41. Su CW, Hung HH, Huo TI et al. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int. 2008 28 : 1305 1313.
42. Iwasaki S, Ohira H, Nishiguchi S et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol. Res. 2008 38 : 557 564.
43. Galsky J, Bansky G, Holubova T, Konig J. Effect of ursodeoxycholic acid in acute viral hepatitis. J. Clin. Gastroenterol. 1999 28 : 249 253.
44. Yusuf TE, Baron TH. AIDS cholangiopathy. Curr. Treat. Options Gastroenterol. 2004 7 : 111 117.
45. Poupon RY, Meyniel D, Petit J, Gustot P, Darnis F Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin Ann. Med. Interne (Paris) 1979 130 : 371 375.
46. Marschall HU, Wagner M, Zollner G et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005 129 : 476 485.
47. Mansour-Ghanaei F, Taheri A, Froutan H et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J. Gastroenterol. 2006 12 : 1125 1128.
48. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997 113 : 1264 1269.
49. Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007 133 : 1603 1613.